Pfizer – Advances in the Management of Ulcerative Colitis (UC) – RFP

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Geographic Scope: Europe, Canada, Japan, South Korea, Australia, New Zealand, Israel

Clinical Area:  Ulcerative Colitis

Link to full RFP: Advances in the Management of Ulcerative Colitis (UC)

Application Due Date: April 30, 2023

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on providing education to healthcare professionals (HCPs) involved in diagnosis, treatment, and management of patients with UC. Proposals should include, but are not limited to the following areas:

• Understanding the S1P receptor modulation MOA and its role in the pathophysiology of UC
• Potential role of S1P receptor modulators in clinical management if UC
• Facilitating shared decision making between the HCP and patient and/or caregiver to select the optimal treatment plan after discussing all available options, their pros and cons, personal preferences, and the circumstances of the patient

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Sarthak Pandit, Grant Officer (sarthak.pandit@pfizer.com).